INTERSPECIES SCALING OF CLEARANCE AND VOLUME OF DISTRIBUTION DATA FOR 5 THERAPEUTIC PROTEINS

被引:154
作者
MORDENTI, J
CHEN, SA
MOORE, JA
FERRAIOLO, BL
GREEN, JD
机构
[1] RW JOHNSON PHARMACEUT RES INST,DEPT DRUG METAB,SPRING HOUSE,PA 19477
[2] GENENTECH INC,DEPT SAFETY EVALUAT,S SAN FRANCISCO,CA 94080
关键词
ALLOMETRIC EQUATION; INTERSPECIES SCALING; THERAPEUTIC PROTEINS; PHARMACOKINETICS; CLEARANCE; VOLUME OF DISTRIBUTION; SOLUBLE RCD4; CD4-IGG; GROWTH HORMONE; TISSUE-PLASMINOGEN ACTIVATOR; RELAXIN;
D O I
10.1023/A:1015836720294
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The clearance and volume of distribution of five human proteins (recombinant CD4, CD4 immunoglobulin G, growth hormone, tissue-plasminogen activator, and relaxin) in humans and laboratory animals were analyzed as a function of body weight using allometric scaling techniques. These proteins cover a 16-fold range of molecular weight (6 to 98 kD), are produced by recombinant or synthetic methods, and may be cleared by different mechanisms. The analyses revealed that the clearance and volume data for each protein were satisfactorily described by an allometric equation (Y = a W(b)). The allometric exponent (b) for clearance (ml/min) ranged from 0.65 to 0.84, the allometric exponent for the initial volume of distribution (ml) ranged from 0.83 to 1.05, and the allometric exponent for the volume of distribution at steady state (ml) ranged from 0.84 to 1.02. Exponent values from 0.6 to 0.8 for clearance and 0.8 to 1.0 for volumes are frequently cited for small molecules and are expected based on empirical interspecies relationships. When the preclinical data were analyzed separately, the preclinical allometric relationships were usually predictive of the human results. These findings indicate that the clearance and volume of distribution of select biomacromolecules follow well-defined, size-related physiologic relationships, and preclinical pharmacokinetic studies provide reasonable estimates of human disposition. Employing this methodology during the early phases of drug development may provide a more rational basis for dose selection in the clinical environment.
引用
收藏
页码:1351 / 1359
页数:9
相关论文
共 55 条
[1]  
ANDREENKO GV, 1983, VOP MED KHIM, V29, P112
[2]  
BAKHIT C, 1987, J BIOL CHEM, V262, P8716
[3]  
BAKHIT C, 1988, Fibrinolysis, V2, P31, DOI 10.1016/0268-9499(88)90062-8
[4]  
BAUGHMAN RA, 1987, TISSUE PLASMINOGEN A, P41
[5]   A SPECIFIC GROWTH HORMONE-BINDING PROTEIN IN HUMAN-PLASMA - INITIAL CHARACTERIZATION [J].
BAUMANN, G ;
STOLAR, MW ;
AMBURN, K ;
BARSANO, CP ;
DEVRIES, BC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 62 (01) :134-141
[6]   THE EFFECT OF CIRCULATING GROWTH HORMONE-BINDING PROTEIN ON METABOLIC-CLEARANCE, DISTRIBUTION, AND DEGRADATION OF HUMAN GROWTH-HORMONE [J].
BAUMANN, G ;
AMBURN, KD ;
BUCHANAN, TA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (04) :657-660
[7]   THE CIRCULATING GROWTH-HORMONE (GH)-BINDING PROTEIN COMPLEX - A MAJOR CONSTITUENT OF PLASMA GH IN MAN [J].
BAUMANN, G ;
AMBURN, K ;
SHAW, MA .
ENDOCRINOLOGY, 1988, 122 (03) :976-984
[8]   INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM [J].
BOXENBAUM, H .
DRUG METABOLISM REVIEWS, 1984, 15 (5-6) :1071-1121
[9]   INTERSPECIES VARIATION IN LIVER WEIGHT, HEPATIC BLOOD-FLOW, AND ANTIPYRINE INTRINSIC CLEARANCE - EXTRAPOLATION OF DATA TO BENZODIAZEPINES AND PHENYTOIN [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1980, 8 (02) :165-176
[10]   INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02) :201-225